Table 4.

Grade 3/4 AEs at least possibly related to ribociclib and/or everolimus among all treated patients.

All patients (N = 20)
Grade
Category/event description34Grade 3 and 4 (% patients)
Investigations
 ALT increased101 (5%)
 Cholesterol higha202 (10%)
 Lymphocyte count decreased (lymphopenia)516 (30%)
 Neutrophil count decreased (neutropenia)505 (25%)
 White blood cell decreased (leukopenia)404 (20%)
Metabolism and nutrition disorders
 Hypokalemia2b02 (10%)
Vascular disorders
 Hypertension101 (5%)
Maximum grade 3 and 4 AE
 Number of patients729 (45%)
  • aAttributed to everolimus only.

  • bOne patient attributed to ribociclib only.